Role of Patient Adherence in Maintenance of Results after Manipulative Therapy for Lymphedema

2006 ◽  
Vol 04 (03) ◽  
pp. 125 ◽  
Author(s):  
Peter A.S. Johnstone ◽  
Kennedy Hawkins ◽  
Stephanie Hood
Keyword(s):  
Patient Adherence ◽  
Manipulative Therapy

Regression of Enlarged Lumbar Zygapophyseal Inclusions after Manipulative Therapy

1998 ◽  
Vol 11 (1) ◽  
pp. 113-116
Author(s):  
V. Rucco ◽  
P.-T. Basadonna ◽  
D. Gasparini
Keyword(s):  
Magnetic Resonance ◽  
Magnetic Resonance Image ◽  
Pain Syndrome ◽  
Spontaneous Pain ◽  
Low Back ◽  
Facet Joints ◽  
Manipulative Therapy ◽  
Facet Syndrome ◽  
Lumbar Facet

We describe a case of low back pain (LBP) secondary to a facet syndrome, with a magnetic resonance image of enlarged zygapophyseal inclusions, which both regressed with manipulative therapy. The role of the lumbar zygapophyseal inclusion in the pain syndrome remains uncertain, because there are no studies on these inclusions in the lumbar facet syndrome. The explanation of the role of manual therapy is also uncertain (adjusting joint subluxations, restoring bony alignment, reducing nuclear protrusion, reducing meniscoid entrapment or extrapment, decompressing facet joints, etc). The diagnosis of classical facet syndrome LBP was made by history-taking and physical examination. The diagnosis of intra-articular enlargements was made by magnetic resonance imaging. The manipulative therapy consisted of manipulations in rotation with the spine placed in kyphosis. Before every manipulation session, spontaneous pain, pain with pressure on the zygapophyseal joint and the range of thoracic and lumbar spine motions were evaluated. After the fourth manipulation session, the patient's pain was alleviated and the enlarged zygapophyseal inclusions were no longer visible. The clinical improvement continued at the controls one and two months after the end of the manipulative therapy. This is the first report of facet syndrome LBP with a magnetic resonance image of enlarged zygapophyseal inclusions which both regressed with manipulative therapy. It is interesting to speculate on the possible mechanisms to explain this outcome, but further studies are needed.

scholarly journals Delivery of patient adherence support: a systematic review of the role of pharmacists and doctors

2014 ◽  
pp. 31 ◽  
Author(s):  
Sara Garfield ◽  
Lina Eliasson ◽  
Christina Jackson ◽  
Malin Andersson ◽  
Theo Raynor
Keyword(s):  
Systematic Review ◽  
Patient Adherence ◽  
Adherence Support

scholarly journals Non-parenteral Therapy for Pulmonary Arterial Hypertension: A Review of Efficacy, Tolerability and Factors Related to Patient Adherence

2011 ◽  
Vol 3 ◽  
pp. CMT.S2689
Author(s):  
Geoff Strange ◽  
Christianne Manterfield ◽  
Trudi Miller ◽  
Annette Pidoux ◽  
Karen Brown ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Patient Adherence ◽  
Multidisciplinary Care ◽  
Premature Death ◽  
Progressive Increase ◽  
Effective Manner ◽  
History Of ◽  
Pulmonary Arterial

Pulmonary arterial hypertension (PAH) is defined as a group of diseases characterized by a progressive increase in pulmonary vascular resistance (PVR) leading to right ventricular failure and premature death. Untreated, it is a potentially devastating disease. However, the past decade has seen remarkable improvements in our understanding of the pathology associated with the condition and the development of multiple PAH-specific therapies with the ability to alter the natural history of the disease. These new advances provide a significant opportunity for practitioners to detect and treat patients with PAH in a timely and effective manner, thereby improving overall mortality, morbidity, and quality of life associated with this disease. The aim of this review is two-fold: firstly to review the evidence for efficacy and safety of non-parenteral PAH therapies and to discuss treatment selection based on clinically meaningful differences among the approved therapies, such as the potential for serious drug-drug interactions, convenience of dosing schedules, and rates of limiting side effects. Secondly, the central role of the PAH clinical nurse in the multidisciplinary care of patients with PAH will be discussed, together with issues relating to adherence and interventions to enhance patient compliance.

Sapropterin: A New Therapeutic Agent for Phenylketonuria

2009 ◽  
Vol 43 (9) ◽  
pp. 1466-1473 ◽  
Author(s):  
Karly A Hegge ◽  
Kristin K Horning ◽  
Gregory J Peitz ◽  
Kassy Hegge
Keyword(s):  
Safety Profile ◽  
English Language ◽  
Phenylalanine Hydroxylase ◽  
Patient Adherence ◽  
Therapeutic Option ◽  
Phase 2 ◽  
Efficacy Data ◽  
Safety And Efficacy

Objective: To summarize the role of pharmacotherapy in the management of phenylketonuria (PKU) and to review the pharmacology, pharmacokinetics, pharmacodynamics, efficacy data, and safety profile of sapropterin for this indication. Data Sources: A literature search was conducted using MEDLINE (1966–May 2009), International Pharmaceutical Abstracts (1970–May 2009), and Cochrane database (2008) for the following key words: sapropterin, tetrahydrobiopterin, phenylketonurias, and phenylalanine. Study Selection and Data Extraction: English-language studies involving humans examining the role of tetrahydrobiopterin (BH4) in the management of PKU were reviewed to evaluate the pharmacology, pharmacokinetics, pharmacodynamics, efficacy data, and safety profile for sapropterin. All Phase 2 and 3 randomized controlled trials assessing the safety and efficacy of sapropterin were included in this literature evaluation. Data Synthesis: Sapropterin represents the only Food and Drug Administration–approved medication for BH4-responsive PKU, marking an important advance in the treatment of this condition. Among individuals with hyperphenylalaninemia and some residual phenylalanine hydroxylase function, sapropterin can enhance activity of this enzyme to decrease serum phenylalanine concentrations. Sapropterin has been compared with placebo in one Phase 2 and one Phase 3 clinical trial, demonstrating significantly better response rates. Based on available studies, this agent appears to be safe and well tolerated, with adverse event rates similar to those of placebo. However, additional studies are warranted to assess the long-term safety and efficacy of sapropterin therapy. Conclusions: Sapropterin offers a promising therapeutic option for select individuals with BH4-responsive PKU, although long-term data are limited evaluating its safety and efficacy in traditional clinical practice settings. When considering sapropterin therapy, clinicians must consider factors such as cost and patient adherence to drug therapy and/or diet.

scholarly journals Hypertension and dyslipidemia. Parallel risk factor control: role of fixed combination

2021 ◽  
Vol 27 (3) ◽  
pp. 376-383
Author(s):  
A. O. Konradi ◽  
A. S. Alieva
Keyword(s):  
Blood Pressure ◽  
Patient Adherence ◽  
Effective Control ◽  
Adherence To Treatment ◽  
Primary And Secondary Prevention ◽  
Risk Factor Control ◽  
Promising Strategy ◽  
Cardiovascular Continuum

The combined effect of dyslipidemia and high blood pressure largely contributes to the development and progression of cardiovascular diseases, and therefore the control of these risk factors should be a priority strategy both within primary and secondary prevention. A concept of a polypill, which provides effective control of both blood pressure and lipid profile, is a promising strategy. It allows of controlling several factors of the cardiovascular continuum, and contributes to a higher patient adherence to treatment. Therefore, the wider implementation of a polypill strategy will improve patients’ prognosis and quality of life.

scholarly journals Development Model of Household Contacts as a Peer Support to Decrease the Prevalence of Pulmonary Tuberculosis

2018 ◽  
Vol 13 (3) ◽  
pp. 404-410
Author(s):  
Suharyo Suharyo ◽  
Kismi Mubarokah
Keyword(s):  
Peer Support ◽  
Patient Adherence ◽  
Household Contact ◽  
Wilcoxon Test ◽  
P Value ◽  
Group Discussions ◽  
Household Contacts ◽  
Global Threat ◽  
Testing And Counseling

Tuberculosis is a global threat, caused mortality of 15 million people in 2014. Drug supervisor is the main strategy in patient adherence. Hence, the need for strengthening the strategy testing and counseling patients by a household contact as a peer support in overcoming the disease. Non randomized one-group pretest-posttest design was used. The identification of the characteristics of the household contact person who will be peer support was done through focus group discussions. Seventeen household contacts became a model of peer support that accompanied each individual patient. Differences in results were used the Wilcoxon test. There was a significant increase of knowledge (p value = 0.03), adherence (p value = 0.02), prevention practice of transmission by patients (p value = 0.03), and the prevalence of pulmonary TB was decreased by 41% after peer support intervention. Peer   support model can be used as an alternative to increase the role of drug supervisor.

Sign in / Sign up

Export Citation Format

Share Document